Struyf, Nona http://orcid.org/0000-0002-6975-0753
Österroos, Albin http://orcid.org/0000-0001-8749-7299
Vesterlund, Mattias http://orcid.org/0000-0001-9471-6592
Arnroth, Cornelia
James, Tojo
Sunandar, Stephanie
Mermelekas, Georgios
Bohlin, Anna
Hamberg Levedahl, Kerstin
Bengtzén, Sofia
Jafari, Rozbeh http://orcid.org/0000-0002-3396-4709
Orre, Lukas M. http://orcid.org/0000-0002-0384-1003
Lehtiö, Janne
Lehmann, Sören
Östling, Päivi
Kallioniemi, Olli
Seashore-Ludlow, Brinton http://orcid.org/0000-0001-8658-5967
Erkers, Tom http://orcid.org/0000-0002-2754-6287
Funding for this research was provided by:
Barncancerfonden (TJ2021-0080)
Karolinska Institutet (2020-01091, 2018-02283)
Stiftelsen för Strategisk Forskning (SB16-0058)
Vetenskapsrådet (2017-06095)
Knut och Alice Wallenbergs Stiftelse (2015.0291)
Article History
Received: 16 June 2023
Accepted: 30 January 2024
First Online: 19 February 2024
Competing interests
: The author O.K. is a co-founder and a board member of Sartar Therapeutics and has received royalty on patents licensed by Vysis-Abbot. None of the other authors have any conflicts of interest to declare.